FINWIRES · TerminalLIVE
FINWIRES

Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List

By

China's drug regulator included Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiary Suzhou Shengdia Biopharmaceutical's ruzaltatug rezetecan drug for non-small cell lung cancer in its breakthrough therapy designation list, according to a Saturday filing with the Shanghai bourse.

The drug is indicated for combination with bevacizumab to treat advanced or metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor tyrosine kinase inhibitors, the filing said.

What else is happening in Asia?

Asia

Shui On Land's 20%-Owned Company to Sell China Property

Shui On Land (HKG:0272) said a company in which it holds a 19.8% stake agreed to sell a property in China to Chongqing Shengjuge Real Estate Agency for 201 million yuan.Chongqing Shui On Tiandi Real Estate Development expects the sale of the commercial site with a gross floor area of 31,287 square meters to support its resource allocation and cash flow, according to a Tuesday filing in Hong Kong.

HKG:0272
Asia

Lisi Group Unit Renews Lease for Factory, Office Property in China

Lisi Group (HKG:0526) unit Ningbo Lisi Household Products renewed the lease of a factory space and office property in China ahead of its Sept. 30 expiry.The new lease agreement signed with lessor Da Mei (Ningbo) New Materials will be effective for three years starting Oct. 1, 2026, and ending Sept. 30, 2029.

HKG:0526
Asia

Hunlicar Group Names Acting Chair

Hunlicar Group (HKG:3638) named CEO Chan Wing Sum as its acting chairman effective Friday, according to a same-day bourse filing.

HKG:3638